Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Becotatug Vedotin Plus Pucotenlimab as First-line Therapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

NCT07381699 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07381699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07381699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Becotatug Vedotin Plus Pucotenlimab as First-line Therapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
February 1, 2030
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancinoma (npc)